Pro- and anti-angiogenic therapy and atherosclerosis with special emphasis on vascular endothelial growth factors

Expert Opinion on Biological Therapy

Volumn 12, Issue 1, 2012, Pages 79-92

  Vuorio, Taina ^a   Jauhiainen, Suvi ^a   Ylä Herttuala, Seppo ^a,b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Angiogenesis; Atherosclerosis; Gene therapy; VEGF A

Indexed keywords

ADENOVIRUS VECTOR; ANGIOGENESIS INHIBITOR; ANGIOPOIETIN 1; BEVACIZUMAB; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 4; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYPOXIA INDUCIBLE FACTOR 1; PAZOPANIB; PLASMID DNA; RECOMBINANT VASCULOTROPIN; RECOMBINANT VASCULOTROPIN A; SCATTER FACTOR; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN 121; VASCULOTROPIN 165; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D;

ANGINA PECTORIS; ANGIOGENESIS; ANTIANGIOGENIC THERAPY; ATHEROSCLEROSIS; BLEEDING; BLOOD TOXICITY; CLINICAL TRIAL (TOPIC); CORONARY ARTERY DISEASE; DRUG SAFETY; DRUG TOLERABILITY; HEART ARRHYTHMIA; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HOMEOSTASIS; HUMAN; HYPERTENSION; HYPOTENSION; ISCHEMIC HEART DISEASE; LIMB ISCHEMIA; MUSCLE ISCHEMIA; NONHUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PERIPHERAL VASCULAR DISEASE; PERMEABILITY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEINURIA; REVIEW; SIDE EFFECT; THROMBOEMBOLISM; VASOCONSTRICTION; VASODILATATION; WOUND HEALING IMPAIRMENT;

ANGIOGENESIS INDUCING AGENTS; ANGIOGENESIS INHIBITORS; ANIMALS; ATHEROSCLEROSIS; CLINICAL TRIALS AS TOPIC; CORONARY ARTERY DISEASE; GENE THERAPY; HUMANS; INFLAMMATION; LYMPHANGIOGENESIS; MALE; MODELS, BIOLOGICAL; PERIPHERAL ARTERIAL DISEASE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84055190123     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2012.641011     Document Type: Review

References (120)

1. Glass CK, Witztum JL. Atherosclerosis. the road ahead. Cell 2001;104:503-16
2. Lusis AJ. Atherosclerosis. Nature 2000;407:233-41
3. Yla-Herttuala S, Palinski W, Rosenfeld ME, et al. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 1989;84:1086-95 (Pubitemid 19247577)
4. Berliner JA, Territo MC, Sevanian A, et al. Minimally modified low density lipoprotein stimulates monocyte endothelial interactions. J Clin Invest 1990;85:1260-6 (Pubitemid 20123772)
5. Cushing SD, Berliner JA, Valente AJ, et al. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci USA 1990;87:5134-8
6. Rajavashisth TB, Andalibi A, Territo MC, et al. Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified low-density lipoproteins. Nature 1990;344:254-7
7. Finn AV, Nakano M, Narula J, et al. Concept of vulnerable/unstable plaque. Arterioscler Thromb Vasc Biol 2010;30:1282-92
8. Davies MJ, Thomas A. Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death. N Engl J Med 1984;310:1137-40 (Pubitemid 14135387)
9. Koch S, Tugues S, Li X, et al. Signal transduction by vascular endothelial growth factor receptors. Biochem J 2011;437:169-83
10. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004;25:581-611 (Pubitemid 39099316)
11. Roy H, Bhardwaj S, Babu M, et al. Adenovirus-mediated gene transfer of placental growth factor to perivascular tissue induces angiogenesis via upregulation of the expression of endogenous vascular endothelial growth factor-A. Hum Gene Ther 2005;16:1422-8 (Pubitemid 41829017)
12. Lahteenvuo JE, Lahteenvuo MT, Kivela A, et al. Vascular endothelial growth factor-B induces myocardium-specific angiogenesis and arteriogenesis via vascular endothelial growth factor receptor-1- and neuropilin receptor-1-dependent mechanisms. Circulation 2009;119:845-56
13. Hagberg CE, Falkevall A, Wang X, et al. Vascular endothelial growth factor B controls endothelial fatty acid uptake. Nature 2010;464:917-21
14. Luttun A, Brusselmans K, Fukao H, et al. Loss of placental growth factor protects mice against vascular permeability in pathological conditions. Biochem Biophys Res Commun 2002;295:428-34 (Pubitemid 34785852)
15. Oura H, Bertoncini J, Velasco P, et al. A critical role of placental growth factor in the induction of inflammation and edema formation. Blood 2003;101:560-7 (Pubitemid 36077578)
16. Anisimov A, Alitalo A, Korpisalo P, et al. Activated forms of VEGF-C and VEGF-D provide improved vascular function in skeletal muscle. Circ Res 2009;104:1302-12
17. Lahteenvuo M, Honkonen K, Tervala T, et al. Growth factor therapy and autologous lymph node transfer in lymphedema. Circulation 2011;123:613-20
18. Jia H, Bagherzadeh A, Bicknell R, et al. Vascular endothelial growth factor (VEGF)-D and VEGF-A differentially regulate KDR-mediated signaling and biological function in vascular endothelial cells. J Biol Chem 2004;279:36148-57 (Pubitemid 39100623)
19. Toivanen PI, Nieminen T, Viitanen L, et al. Novel vascular endothelial growth factor D variants with increased biological activity. J Biol Chem 2009;284:16037-48
20. Rutanen J, Rissanen TT, Markkanen JE, et al. Adenoviral catheter-mediated intramyocardial gene transfer using the mature form of vascular endothelial growth factor-D induces transmural angiogenesis in porcine heart. Circulation 2004;109:1029-35
21. Harris NC, Paavonen K, Davydova N, et al. Proteolytic processing of vascular endothelial growth factor-D is essential for its capacity to promote the growth and spread of cancer. FASEB J 2011;25:2615-25
22. Yamazaki Y, Takani K, Atoda H, Morita T. Snake venom vascular endothelial growth factors (VEGFs) exhibit potent activity through their specific recognition of KDR (VEGF receptor 2). J Biol Chem 2003;278:51985-8
23. Matsunaga Y, Yamazaki Y, Suzuki H, Morita T. VEGF-A and VEGF-F evoke distinct changes in vascular ultrastructure. Biochem Biophys Res Commun 2009;379:872-5
24. Tammela T, Enholm B, Alitalo K, Paavonen K. The biology of vascular endothelial growth factors. Cardiovasc Res 2005;65:550-63 (Pubitemid 40138976)
25. Couffinhal T, Kearney M, Witzenbichler B, et al. Vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) in normal and atherosclerotic human arteries. Am J Pathol 1997;150:1673-85 (Pubitemid 27193815)
26. Inoue M, Itoh H, Ueda M, et al. Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions: Possible pathophysiological significance of VEGF in progression of atherosclerosis. Circulation 1998;98:2108-16 (Pubitemid 28527469)
27. Rutanen J, Leppanen P, Tuomisto TT, et al. Vascular endothelial growth factor-D expression in human atherosclerotic lesions. Cardiovasc Res 2003;59:971-9 (Pubitemid 38366253)
28. Roy H, Bhardwaj S, Yla-Herttuala S. Molecular genetics of atherosclerosis. Hum Genet 2009;125:467-91
29. Sobti RC, Maithil N, Thakur H, et al. VEGF and IL-4 gene variability and its association with the risk of coronary heart disease in north indian population. Mol Cell Biochem 2010;341:139-48
30. Alber HF, Frick M, Dulak J, et al. Vascular endothelial growth factor (VEGF) plasma concentrations in coronary artery disease. Heart 2005;91:365-6 (Pubitemid 40299222)
31. Pilarczyk K, Sattler KJ, Galili O, et al. Placenta growth factor expression in human atherosclerotic carotid plaques is related to plaque destabilization. Atherosclerosis 2008;196:333-40
32. Nakano T, Nakashima Y, Yonemitsu Y, et al. Angiogenesis and Pro- and anti-angiogenic therapy and atherosclerosis with special emphasis on vascular endothelial growth factors 88 Expert Opin. Biol. Ther. (2012) 12(1) lymphangiogenesis and expression of lymphangiogenic factors in the atherosclerotic intima of human coronary arteries. Hum Pathol 2005;36:330-40
33. Zamir M, Silver MD. Vasculature in the walls of human coronary arteries. Arch Pathol Lab Med 1985;109:659-62 (Pubitemid 15233246)
34. Sueishi K, Yonemitsu Y, Nakagawa K, et al. Atherosclerosis and angiogenesis. Its pathophysiological significance in humans as well as in an animal model induced by the gene transfer of vascular endothelial growth factor. Ann NY Acad Sci 1997;811:311-24 (Pubitemid 27308337)
35. Sluimer JC, Gasc JM, van Wanroij JL, et al. Hypoxia, hypoxia-inducible transcription factor, and macrophages in human atherosclerotic plaques are correlated with intraplaque angiogenesis. J Am Coll Cardiol 2008;51:1258-65 (Pubitemid 351400903)
36. Khurana R, Simons M, Martin JF, Zachary IC. Role of angiogenesis in cardiovascular disease: a critical appraisal. Circulation 2005;112:1813-24 (Pubitemid 41368158)
37. O'Brien KD, Allen MD, McDonald TO, et al. Vascular cell adhesion molecule-1 is expressed in human coronary atherosclerotic plaques. implications for the mode of progression of advanced coronary atherosclerosis. J Clin Invest 1993;92:945-51 (Pubitemid 23262418)
38. O'Brien KD, McDonald TO, Chait A, et al. Neovascular expression of E-selectin, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in human atherosclerosis and their relation to intimal leukocyte content. Circulation 1996;93:672-82 (Pubitemid 26052452)
39. de Boer OJ, van der Wal AC, Teeling P, Becker AE. Leucocyte recruitment in rupture prone regions of lipid-rich plaques: A prominent role for neovascularization? Cardiovasc Res 1999;41:443-9 (Pubitemid 29087340)
40. Kumamoto M, Nakashima Y, Sueishi K. Intimal neovascularization in human coronary atherosclerosis: Its origin and pathophysiological significance. Hum Pathol 1995;26:450-6
41. Sluimer JC, Daemen MJ. Novel concepts in atherogenesis: Angiogenesis and hypoxia in atherosclerosis. J Pathol 2009;218:7-29
42. Kolodgie FD, Gold HK, Burke AP, et al. Intraplaque hemorrhage and progression of coronary atheroma. N Engl J Med 2003;349:2316-25 (Pubitemid 37509739)
43. Barger AC, Beeuwkes R III. Rupture of coronary vasa vasorum as a trigger of acute myocardial infarction. Am J Cardiol 1990;66:41G-3G (Pubitemid 20384283)
44. Moreno PR, Purushothaman KR, Fuster V, et al. Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: Implications for plaque vulnerability. Circulation 2004;110:2032-8 (Pubitemid 39331918)
45. Kholova I, Dragneva G, Cermakova P, et al. Lymphatic vasculature is increased in heart valves, ischaemic and inflamed hearts and in cholesterol-rich and calcified atherosclerotic lesions. Eur J Clin Invest 2011;41:487-97
46. Yla-Herttuala S, Alitalo K. Gene transfer as a tool to induce therapeutic vascular growth. Nat Med 2003;9:694-701 (Pubitemid 36749218)
47. Zachary I, Morgan RD. Therapeutic angiogenesis for cardiovascular disease: Biological context, challenges, prospects. Heart 2011;97:181-9
48. Gowdak LH, Poliakova L, Wang X, et al. Adenovirus-mediated VEGF121 gene transfer stimulates angiogenesis in normoperfused skeletal muscle and preserves tissue perfusion after induction of ischemia. Circulation 2000;102:565-71 (Pubitemid 30639975)
49. Poliakova L, Kovesdi I, Wang X, et al. Vascular permeability effect of adenovirus-mediated vascular endothelial growth factor gene transfer to the rabbit and rat skeletal muscle. J Thorac Cardiovasc Surg 1999;118:339-47 (Pubitemid 29360337)
50. Vajanto I, Rissanen TT, Rutanen J, et al. Evaluation of angiogenesis and side effects in ischemic rabbit hindlimbs after intramuscular injection of adenoviral vectors encoding VEGF and LacZ. J Gene Med 2002;4:371-80 (Pubitemid 40277174)
51. Muhlhauser J, Pili R, Merrill MJ, et al. In vivo angiogenesis induced by recombinant adenovirus vectors coding either for secreted or nonsecreted forms of acidic fibroblast growth factor. Hum Gene Ther 1995;6:1457-65
52. Ueno H, Li JJ, Masuda S, et al. Adenovirus-mediated expression of the secreted form of basic fibroblast growth factor (FGF-2) induces cellular proliferation and angiogenesis in vivo. Arterioscler Thromb Vasc Biol 1997;17:2453-60 (Pubitemid 28015981)
53. Li X, Tjwa M, Moons L, et al. Revascularization of ischemic tissues by PDGF-CC via effects on endothelial cells and their progenitors. J Clin Invest 2005;115:118-27 (Pubitemid 40385512)
54. Karvinen H, Pasanen E, Rissanen TT, et al. Long-term VEGF-A expression promotes aberrant angiogenesis and fibrosis in skeletal muscle. Gene Ther 2011;published online 12 May 2011 (correction added 9 June 2011); doi:10.1038/gt.2011.66
55. Rissanen TT, Yla-Herttuala S. Current status of cardiovascular gene therapy. Mol Ther 2007;15:1233-47 (Pubitemid 46965318)
56. Henry TD, Annex BH, McKendall GR, et al. The VIVA trial: Vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation 2003;107:1359-65 (Pubitemid 36350732)
57. Hendel RC, Henry TD, Rocha-Singh K, et al. Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion: Evidence for a dose-dependent effect. Circulation 2000;101:118-21 (Pubitemid 30044247)
58. Baumgartner I, Pieczek A, Manor O, et al. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 1998;97:1114-23 (Pubitemid 28152883)
59. Laitinen M, Hartikainen J, Hiltunen MO, et al. Catheter-mediated vascular endothelial growth factor gene transfer to human coronary arteries after angioplasty. Hum Gene Ther 2000;11:263-70 (Pubitemid 30080384)
60. Kastrup J, Jorgensen E, Ruck A, et al. Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris A randomized double-blind placebo-controlled study: the euroinject one trial. J Am Coll Cardiol 2005;45:982-8 (Pubitemid 40432426)
61. Stewart DJ, Kutryk MJ, Fitchett D, et al. VEGF gene therapy fails to improve perfusion of ischemic myocardium in patients with advanced coronary disease: Results of the NORTHERN trial. Mol Ther 2009;17:1109-15
62. Kusumanto YH, van Weel V, Mulder NH, et al. Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: a double-blind Vuorio, Jauhiainen & Ylä-Herttuala Expert Opin. Biol. Ther. (2012) 12(1) 89 randomized trial. Hum Gene Ther 2006;17:683-91
63. Makinen K, Manninen H, Hedman M, et al. Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded Phase II study. Mol Ther 2002;6:127-33 (Pubitemid 36124280)
64. Stewart DJ, Hilton JD, Arnold JM, et al. Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF(121) (AdVEGF121) versus maximum medical treatment. Gene Ther 2006;13:1503-11 (Pubitemid 44574158)
65. Rajagopalan S, Mohler ER III, Lederman RJ, et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: A Phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 2003;108:1933-8 (Pubitemid 37296537)
66. Kastrup J, Jorgensen E, Fuchs S, et al. A randomised, double-blind, placebo-controlled, multicentre study of the safety and efficacy of BIOBYPASS (AdGVVEGF121.10NH) gene therapy in patients with refractory advanced coronary artery disease: The NOVA trial. EuroIntervention 2011;6:813-18
67. Kuopio University Hospital. Endocardial Vascular Endothelial Growth Factor D (VEGF-D) Gene Therapy for the Treatment of Severe Coronary Heart Disease (KAT301).ClinicalTrials.gov NCT01002430. Available from: http://clinicaltrials.gov/ct2/show/NCT01002430?term=VEGF-D&rank=1
68. Celletti FL, Waugh JM, Amabile PG, et al. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med 2001;7:425-9 (Pubitemid 32298544)
69. Celletti FL, Hilfiker PR, Ghafouri P, Dake MD. Effect of human recombinant vascular endothelial growth factor165 on progression of atherosclerotic plaque. J Am Coll Cardiol 2001;37:2126-30 (Pubitemid 32548008)
70. Lucerna M, Zernecke A, de Nooijer R, et al. Vascular endothelial growth factor-A induces plaque expansion in ApoE knock-out mice by promoting de novo leukocyte recruitment. Blood 2007;109:122-9 (Pubitemid 46053052)
71. Leppanen P, Koota S, Kholova I, et al. Gene transfers of vascular endothelial growth factor-A, vascular endothelial growth factor-B, vascular endothelial growth factor-C, and vascular endothelial growth factor-D have no effects on atherosclerosis in hypercholesterolemic low-density lipoprotein-receptor/apolipoprotein B48-deficient mice. Circulation 2005;112:1347-52 (Pubitemid 41266731)
72. Korpisalo P, Hytonen JP, Laitinen JT, et al. Capillary enlargement, not sprouting angiogenesis, determines beneficial therapeutic effects and side effects of angiogenic gene therapy. Eur Heart J 2011;32:1664-72
73. Hedman M, Hartikainen J, Syvanne M, et al. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: Phase II results of the kuopio angiogenesis trial (KAT). Circulation 2003;107:2677-83 (Pubitemid 36667240)
74. Hedman M, Muona K, Hedman A, et al. Eight-year safety follow-up of coronary artery disease patients after local intracoronary VEGF gene transfer. Gene Ther 2009;16:629-34
75. Wang Y, Zhou Y, He L, et al. Gene delivery of soluble vascular endothelial growth factor receptor-1 (sFlt-1) inhibits intra-plaque angiogenesis and suppresses development of atherosclerotic plaque. Clin Exp Med 2011;11:113-21
76. Hauer AD, van Puijvelde GH, Peterse N, et al. Vaccination against VEGFR2 attenuates initiation and progression of atherosclerosis. Arterioscler Thromb Vasc Biol 2007;27:2050-7 (Pubitemid 47312317)
77. Moulton KS, Heller E, Konerding MA, et al. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation 1999;99:1726-32 (Pubitemid 29162486)
78. Moulton KS, Vakili K, Zurakowski D, et al. Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis. Proc Natl Acad Sci USA 2003;100:4736-41 (Pubitemid 36457799)
79. Ahmed A, Fujisawa T, Niu XL, et al. Angiopoietin-2 confers atheroprotection in apoE-/- mice by inhibiting LDL oxidation via nitric oxide. Circ Res 2009;104:1333-6
80. Tugues S, Koch S, Gualandi L, et al. Vascular endothelial growth factors and receptors: Anti-angiogenic therapy in the treatment of cancer. Mol Aspects Med 2011;32:88-111
81. Stefanadis C, Toutouzas K, Stefanadi E, et al. First experimental application of bevacizumab-eluting PC coated stent for inhibition of vasa vasorum of atherosclerotic plaque: Angiographic results in a rabbit atheromatic model. Hellenic J Cardiol 2006;47:7-10
82. Stefanadis C, Toutouzas K, Stefanadi E, et al. Inhibition of plaque neovascularization and intimal hyperplasia by specific targeting vascular endothelial growth factor with bevacizumab-eluting stent: an experimental study. Atherosclerosis 2007;195:269-76 (Pubitemid 350087955)
83. Stefanadis C, Toutouzas K, Stefanadi E, et al. Avastin-eluting stent: Long-term angiographic and clinical follow up.Hellenic J Cardiol 2008;49:188-90 (Pubitemid 351792648)
84. Stefanadis C, Toutouzas K, Tsiamis E, et al. First-in-man study with bevacizumab-eluting stent: a new approach for the inhibition of atheromatic plaque neovascularisation. EuroIntervention 2008;3:460-4
85. Lee S, Chen TT, Barber CL, et al. Autocrine VEGF signaling is required for vascular homeostasis. Cell 2007;130:691-703 (Pubitemid 47268059)
86. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized Phase III trial. J Clin Oncol 2010;28:1061-8
87. Schmidinger M, Zielinski CC, Vogl UM, et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2008;26:5204-12
88. Leighl NB, Raez LE, Besse B, et al. A multicenter, phase 2 study of vascular Pro- and anti-angiogenic therapy and atherosclerosis with special emphasis on vascular endothelial growth factors 90 Expert Opin. Biol. Ther. (2012) 12(1) endothelial growth factor trap (aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lung. J Thorac Oncol 2010;5:1054-9
89. Randall LM, Monk BJ. Bevacizumab toxicities and their management in ovarian cancer. Gynecol Oncol 2010;117:497-504
90. Koponen JK, Kekarainen T, Heinonen SE, et al. Umbilical cord blood-derived progenitor cells enhance muscle regeneration in mouse hindlimb ischemia model. Mol Ther 2007;15:2172-7 (Pubitemid 350148934)
91. Korpisalo P, Karvinen H, Rissanen TT, et al. Vascular endothelial growth factor-A and platelet-derived growth factor-B combination gene therapy prolongs angiogenic effects via recruitment of interstitial mononuclear cells and paracrine effects rather than improved pericyte coverage of angiogenic vessels. Circ Res 2008;103:1092-9
92. Hedman M, Hartikainen J, Yla-Herttuala S. Progress and prospects: Hurdles to cardiovascular gene therapy clinical trials. Gene Ther 2011;18:743-9
93. Martin-Rendon E, Snowden JA, Watt SM. Stem cell-related therapies for vascular diseases. Transfus Med 2009;19:159-71
94. Strauer BE, Steinhoff G. 10 years of intracoronary and intramyocardial bone marrow stem cell therapy of the heart: From the methodological origin to clinical practice. J Am Coll Cardiol 2011;58:1095-104
95. Beltrami AP, Barlucchi L, Torella D, et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 2003;114:763-76 (Pubitemid 37186770)
96. Kinnaird T, Stabile E, Burnett MS, et al. Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ Res 2004;94:678-85 (Pubitemid 38387752)
97. Assmus B, Rolf A, Erbs S, et al. Clinical outcome 2 years after intracoronary administration of bone marrow-derived progenitor cells in acute myocardial infarction. Circ Heart Fail 2010;3:89-96
98. Gyongyosi M, Lang I, Dettke M, et al. Combined delivery approach of bone marrow mononuclear stem cells early and late after myocardial infarction: The MYSTAR prospective, randomized study. Nat Clin Pract Cardiovasc Med 2009;6:70-81
99. Beitnes JO, Gjesdal O, Lunde K, et al. Left ventricular systolic and diastolic function improve after acute myocardial infarction treated with acute percutaneous coronary intervention, but are not influenced by intracoronary injection of autologous mononuclear bone marrow cells: a 3 year serial echocardiographic sub-study of the randomized-controlled ASTAMI study. Eur J Echocardiogr 2011;12:98-106
100. Iwaguro H, Yamaguchi J, Kalka C, et al. Endothelial progenitor cell vascular endothelial growth factor gene transfer for vascular regeneration. Circulation 2002;105:732-8 (Pubitemid 34157378)
101. Matsumoto R, Omura T, Yoshiyama M, et al. Vascular endothelial growth factor-expressing mesenchymal stem cell transplantation for the treatment of acute myocardial infarction. Arterioscler Thromb Vasc Biol 2005;25:1168-73 (Pubitemid 40776604)
102. Cho SW, Kim IK, Bhang SH, et al. Combined therapy with human cord blood cell transplantation and basic fibroblast growth factor delivery for treatment of myocardial infarction. Eur J Heart Fail 2007;9:974-85 (Pubitemid 47451805)
103. Silvestre JS, Gojova A, Brun V, et al. Transplantation of bone marrow-derived mononuclear cells in ischemic apolipoprotein E-knockout mice accelerates atherosclerosis without altering plaque composition. Circulation 2003;108:2839-42 (Pubitemid 37517809)
104. Yoon YS, Park JS, Tkebuchava T, et al. Unexpected severe calcification after transplantation of bone marrow cells in acute myocardial infarction. Circulation 2004;109:3154-7
105. Kang HJ, Kim HS, Zhang SY, et al. Effects of intracoronary infusion of peripheral blood stem-cells mobilized with granulocyte-colony stimulating factor on left ventricular systolic function and restenosis after coronary stenting in myocardial infarction: The MAGIC cell randomised clinical trial. Lancet 2004;363:751-6
106. Villa A, Sanchez PL, Fernandez-Aviles F; Terapia Celular Aplicada al Miocardio Research Group. Ventricular arrhythmias following intracoronary bone marrow stem cell transplantation. Europace 2007;9:1222-3 (Pubitemid 351773251)
107. Simons M, Annex BH, Laham RJ, et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: Double-blind, randomized, controlled clinical trial. Circulation 2002;105:788-93 (Pubitemid 34174916)
108. Lederman RJ, Mendelsohn FO, Anderson RD, et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet 2002;359:2053-8 (Pubitemid 34680967)
109. Seiler C, Pohl T, Wustmann K, et al. Promotion of collateral growth by granulocyte-macrophage colonystimulating factor in patients with coronary artery disease: A randomized, double-blind, placebo-controlled study. Circulation 2001;104:2012-17 (Pubitemid 33027039)
110. Kukula K, Chojnowska L, Dabrowski M, et al. Intramyocardial plasmid-encoding human vascular endothelial growth factor A165/basic fibroblast growth factor therapy using percutaneous transcatheter approach in patients with refractory coronary artery disease (VIF-CAD). Am Heart J 2011;161:581-9
111. Corautus Genetics Announces Final Efficacy Results of GENASIS Phase IIb Clinical Trial. Medical News Today. Available from: http://www.medicalnewstoday. com/releases/53786.php [Last accessed 17 November 2011]
112. Powell RJ, Simons M, Mendelsohn FO, et al. Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia. Circulation 2008;118:58-65
113. Nikol S, Baumgartner I, Van Belle E, et al. Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia. Mol Ther 2008;16:972-8 (Pubitemid 351587109)
114. Belch J, Hiatt WR, Baumgartner I, et al. Effect of fibroblast growth factor NV1FGF on amputation and death: a randomised placebo-controlled trial of gene therapy in critical limb ischaemia. Lancet 2011;377:1929-37
115. Grossman PM, Mendelsohn F, Henry TD, et al. Results from a phase II Vuorio, Jauhiainen & Ylä-Herttuala Expert Opin. Biol. Ther. (2012) 12(1) 91 multicenter, double-blind placebocontrolled study of del-1 (VLTS-589) for intermittent claudication in subjects with peripheral arterial disease. Am Heart J 2007;153(5):874-80
116. Kapur NK, Rade JJ. Fibroblast growth factor 4 gene therapy for chronic ischemic heart disease. Trends Cardiovasc Med 2008;18:133-41 (Pubitemid 351794542)
117. Henry TD, Grines CL, Watkins MW, et al. Effects of Ad5FGF-4 in patients with angina: an analysis of pooled data from the AGENT-3 and AGENT-4 trials. J Am Coll Cardiol 2007;50:1038-46 (Pubitemid 47354223)
118. Cardium Therapeutics. Angiogenesis in Women with Angina Pectoris Who are not candidates for Revascularization (AWARE). ClinicalTrials.gov NCT00438867. Available from: http://clinicaltrials.gov/ct2/show/NCT00438867?term= FGF4&srank=3
119. Creager MA, Olin JW, Belch JJ, et al. Effect of hypoxia-inducible factor-1alpha gene therapy on walking performance in patients with intermittent claudication. Circulation 2011;124:1765-73
120. MultiGene Vascular Systems Ltd. Safety Study of MultiGeneAngio in Patients With Chronic Critical Limb Ischemia. ClinicalTrials.gov NCT00956332. Available from: http://clinicaltrials.gov/ct2/show/NCT00956332